SCHEMBL3344622

SCHEMBL3344622

O=S(=O)(O)C(O)c1ccccc1S(=O)(=O)N1CCCC1.[NaH]

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.50
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
ALDH1A1 P00352 7/20 0.46
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
GAA P10253 1/20 0.41
LMNA P02545 3/20 0.40
ATM Q13315 1/20 0.40
CYP1A2 P05177 1/20 0.40
MCL1 Q07820 1/20 0.40
HTT P42858 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9900047 0.98 TSHR (0.59) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL15844498 0.85 TSHR (0.62) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL14456672 0.78 TSHR (0.65) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL24498674 0.76 TSHR (0.68) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL9962277 0.76 TSHR (0.68) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL19259817 0.75 TSHR (0.71) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL8939649 0.72 TSHR (0.57) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL13937389 0.72 ALDH1A1 (0.45) TSHRSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL4367399 0.72 TSHR (0.71) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL5668217 0.71 TSHR (0.69) TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140187795-A1 CRTH2 MODULATORS AND PREPARATION THEREOF IRONWOOD PHARMACEUTICALS, INC. (US) 2014-07-03 US disclosed
US-20110312945-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. 2011-12-22 US disclosed
WO-2010039982-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312945-A1 CRTH2 MODULATORS HRH2, HRH1, NR1H2 TSHR 356/4885CYP2C9 3663/4885CYP2C19 2812/4885
US-20140187795-A1 CRTH2 MODULATORS AND PREPARATION THEREOF NR1H2, NR3C2, ARRB1 TSHR 296/4885CYP2C9 2355/4885CYP2C19 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.